Dec. 29 at 8:57 PM
$IFRX I dunno about all this depression here.
To me: good time to double down now, until news related to PG unblinding.
Zooming out I see:
This stock is dirt cheap.
BP needs:
Human proof of biology
Clean pharmacokinetics
Multi indication signals
Acceptable safety
Clear path to P2b
All that is given.
BP sees:
C5aR antagonist, oral -> rare
$
$BN indications
Unmet need in HS &CSU
Validated mechanism
Biology de-risked but early -> discount
Small corp -> easy to transact
No poison pill
Small market cap
Validated ("best in class") but not priced.
BP naturally has little interest in driving prices prematurely.
Mcap ≠ fair enterprise value
What's negotiated behind doors (future control) is driving EV.
Yeah, this board is looking for short term symptoms: cash clarity, partner, catalyst. But that's result of behind doors stuff.